UNIVERSITY OF UTAH RESEARCHERS DEVELOP FASTER, MORE ACCURATE TEST FOR LIVER CANCER THAT CAN BE ADMINISTERED ANYWHERE
It’s estimated that about 788,000 people worldwide died of liver cancer in 2015, the second-leading cause of cancer deaths, according to the latest statistics from the World Health Organization. One of the major challenges in combatting this disease is detecting it early because symptoms often don’t appear until later stages.
But a team of researchers led by University of Utah chemical engineering and chemistry professor Marc Porter and U surgeon and professor Courtney Scaife has developed a rapid portable screening test for liver cancer (hepatocellular carcinoma) that doesn’t involve sending a specimen to a blood lab and cuts the wait time for results from two weeks to two minutes. This new and inexpensive test — the team is working to lower the cost to about $3 per test — can be administered wherever the patient is, which will be particularly valuable in developing nations with little access to hospitals.
The test uses a small domino-sized plastic cartridge containing a paper membrane that selectively traps biomarkers (proteins specific to a certain disease) from biological fluids. A small droplet of blood, saliva, or urine, or even a teardrop, from the patient is dropped onto the membrane. This is followed by the droplet of gold nanoparticles, which tags the biomarkers trapped in the membrane. If the biomarkers are present, a red spot appears, signaling the patient has the disease and should seek more testing and possible treatment.
“The concept is similar to a home pregnancy test, but instead of flowing laterally, it flows through the membrane,” says Granger, the lead author on the paper.
A handheld spectrometer manufactured by project collaborator B&W Tek, a Delaware-based manufacturer of mobile spectrometers, can analyze the membranes and measure how much of the biomarkers is present, which in the future could determine the severity of the disease or how a patient is responding to treatment.
The idea for the test is a spinoff of a similar test Porter developed eight years ago that astronauts on the International Space Station used to test the cleanliness of their drinking water. “This is a smarter offshoot of that,” says Porter, who also is the director of the Nano Institute of Utah.
Now that the team has proven the concept with liver cancer and built a prototype test kit, researchers plan to evaluate the technology in Mongolia in spring of 2019. The East Asian country has the highest rate of liver cancer in the world.
The project was funded by grants from the National Institutes of Health, the National Cancer Institute through the Affordable Cancer Technologies Program and the Huntsman Cancer Institute. The team also received funding from Utah-based nutritional supplement company USANA which is interested in using a form of the test for customers with certain vitamin deficiencies.
“USANA has a keen interest in the ability to measure certain vitamins and biomarkers in various bodily fluids that can be related to a person’s health status,” said Mark Brown, Executive Director of Laboratory Sciences at USANA. “This would allow our customers to see for themselves the benefit of taking USANA’s high quality products. Rather than taking a blood sample and sending it off to lab for analysis, this technology could make it possible for people to do their own analysis in the comfort of their own home. Small sample size and simplicity of use are crucial components of making this a reality, and this research is a step closer to that end.”
Learn more: PUTTING IT TO THE TEST
The Latest on: Liver cancer
- Legendary Hong Kong actor Ng Man-tat dies of liver cancer at 70on February 27, 2021 at 1:56 pm
Born in Xiamen in 1951, he came to city as a child and rose to fame in 1980s, eventually becoming a household name for co-starring with Stephen Chow.
- Hundreds of people set to benefit as NICE recommends selective internal radiation therapy for treating advanced liver canceron February 26, 2021 at 3:38 am
Home; News; Hundreds of people set to benefit as NICE recommends selective internal radiation therapy for treating advanced liver cancer Hundreds of people with advanced liver can ...
- Current screening guidelines may not detect liver cancer soon enough in African Americanson February 25, 2021 at 3:48 pm
Early detection could reduce the number of African Americans dying from liver cancer, but current screening guidelines may not find cancer soon enough in this community, according to a study published ...
- SOX9-transactived long non-coding RNA NEAT1 promotes the self-renewal of liver cancer stem cells through PKA/Hippo signalingon February 25, 2021 at 3:37 pm
Long non-coding RNAs (LncRNAs) are defined as RNA transcripts >200 nucleotides (nt) in length without protein-coding potential, which have been reported to be involved in organ development, stemness ...
- Why Is Liver Cancer More Lethal for Black Patients?on February 25, 2021 at 9:26 am
Despite often being more advanced, liver cancer in Black people is slower to cause liver damage and scarring, and current guidelines call for liver cancer screening only after such scarring (cirrhosis ...
- Current liver cancer screenings may leave African Americans at greater riskon February 25, 2021 at 8:32 am
Early detection could reduce the number of African Americans dying from liver cancer, but current screening guidelines may not find cancer soon enough in this community, according to a study ...
- Berry Oncology Announces Novel Diagnostic Method for Liver Cancer Achieved Greater Accuracy and Sensitivity Compared to Existing Non-Invasive Methodson February 24, 2021 at 5:37 am
Berry Oncology Corporation, the shareholding subsidiary of Berry Genomics, announced the results of a case-control study on the effectiveness of a novel diagnostic method for detecting hepatocellular ...
- New Positive Data from Can-Fite’s Liver Cancer Phase II Clinical Study with Namodenosonon February 22, 2021 at 9:10 am
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address in ...
- Never-before-seen antibody binding, informing liver cancer, antibody designon February 17, 2021 at 7:38 pm
In structural biology, some molecules are so unusual they can only be captured with a unique set of tools. That's precisely how a team defined how antibodies can recognize a compound called ...
- Salk team reveals never-before-seen antibody binding, informing liver cancer, antibody designon February 17, 2021 at 2:08 pm
In structural biology, some molecules are so unusual they can only be captured with a unique set of tools. That's precisely how a team led by Salk scientists defined how antibodies can recognize a ...
via Google News and Bing News